Du et al. found that circNFIB may be used as a biomarker for intrahepatic cholangiocarcinoma (ICC) patients, and the circNFIB-MEK-ERK axis may be a potential therapeutic target for ICC treatment [37]. Here, MAP2K7 is linked to intrahepatic cholangiocarcinoma.